Is pelvic lymph node dissection required at radical prostatectomy for low‐risk prostate cancer?
Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Yoichi Arai(Japan Atomic Energy Agency), Yasuhiro Kaiho(Tohoku University), Shintaro Narita(Akita University), Takuya Koie(Hirosaki University), Chikara Οhyama(Hirosaki University), Tohru Yoneyama(Hirosaki University), Tomonori Habuchi(Akita University), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization)
Cited by 22
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253
Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract.
|PubMed|1998|176
ANATOMICAL ANALYSIS OF THE NEUROVASCULAR BUNDLE SUPPLYING PENILE CAVERNOUS TISSUE TO ENSURE A RELIABLE NERVE GRAFT AFTER RADICAL PROSTATECTOMY
|The Journal of Urology|2004|159
Prognostic Significance of Prostate Specific Antigen in Endocrine Treatment for Prostatic Cancer
|The Journal of Urology|1990|122